PSTV Quote, Financials, Valuation and Earnings

GlucoTrack has a net margin of -- compared to Plus Therapeutics's net margin of --. Plus Therapeutics's return on equity of -- beat GlucoTrack's return on equity of --.

Plus Therapeutics has a consensus price target of $9.17, signalling upside risk potential of 2293.39%. On the other hand GlucoTrack has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics has higher upside potential than GlucoTrack, analysts believe Plus Therapeutics is more attractive than GlucoTrack.

Plus Therapeutics has a beta of 0.693, which suggesting that the stock is 30.722% less volatile than S&P 500. In comparison GlucoTrack has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.622%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. GlucoTrack pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than GlucoTrack quarterly revenues of --. Plus Therapeutics's net income of -$17.4M is lower than GlucoTrack's net income of -$6.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while GlucoTrack's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.63x versus 6.90x for GlucoTrack. Usually stocks with elevated PS ratios are considered overvalued.

Lifeward has a net margin of -- compared to Plus Therapeutics's net margin of -96.03%. Plus Therapeutics's return on equity of -- beat Lifeward's return on equity of -92.59%.

Plus Therapeutics has a consensus price target of $9.17, signalling upside risk potential of 2293.39%. On the other hand Lifeward has an analysts' consensus of $8.67 which suggests that it could grow by 1065.5%. Given that Plus Therapeutics has higher upside potential than Lifeward, analysts believe Plus Therapeutics is more attractive than Lifeward.

Plus Therapeutics has a beta of 0.693, which suggesting that the stock is 30.722% less volatile than S&P 500. In comparison Lifeward has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.425%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Lifeward quarterly revenues of $5M. Plus Therapeutics's net income of -$17.4M is lower than Lifeward's net income of -$4.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.63x versus 0.27x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Plus Therapeutics's net margin of -2201.34%. Plus Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Plus Therapeutics has a consensus price target of $9.17, signalling upside risk potential of 2293.39%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 334.72%. Given that Plus Therapeutics has higher upside potential than VolitionRX, analysts believe Plus Therapeutics is more attractive than VolitionRX.

Plus Therapeutics has a beta of 0.693, which suggesting that the stock is 30.722% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Plus Therapeutics's net income of -$17.4M is lower than VolitionRX's net income of -$5.4M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.63x versus 46.61x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Plus Therapeutics's net margin of 0.18%. Plus Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Plus Therapeutics has a consensus price target of $9.17, signalling upside risk potential of 2293.39%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 182.26%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.

Plus Therapeutics has a beta of 0.693, which suggesting that the stock is 30.722% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Plus Therapeutics's net income of -$17.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.63x versus 0.69x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.